Nature Communications (Jun 2017)
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
- Todd Bradley,
- Justin Pollara,
- Sampa Santra,
- Nathan Vandergrift,
- Srivamshi Pittala,
- Chris Bailey-Kellogg,
- Xiaoying Shen,
- Robert Parks,
- Derrick Goodman,
- Amanda Eaton,
- Harikrishnan Balachandran,
- Linh V. Mach,
- Kevin O. Saunders,
- Joshua A. Weiner,
- Richard Scearce,
- Laura L. Sutherland,
- Sanjay Phogat,
- Jim Tartaglia,
- Steven G. Reed,
- Shiu-Lok Hu,
- James F. Theis,
- Abraham Pinter,
- David C. Montefiori,
- Thomas B. Kepler,
- Kristina K. Peachman,
- Mangala Rao,
- Nelson L. Michael,
- Todd J. Suscovich,
- Galit Alter,
- Margaret E. Ackerman,
- M. Anthony Moody,
- Hua-Xin Liao,
- Georgia Tomaras,
- Guido Ferrari,
- Bette T. Korber,
- Barton F. Haynes
Affiliations
- Todd Bradley
- Duke Human Vaccine Institute, Duke University Medical Center
- Justin Pollara
- Duke Human Vaccine Institute, Duke University Medical Center
- Sampa Santra
- Beth Israel Deaconess Medical Center, Harvard Medical School
- Nathan Vandergrift
- Duke Human Vaccine Institute, Duke University Medical Center
- Srivamshi Pittala
- Dartmouth College
- Chris Bailey-Kellogg
- Dartmouth College
- Xiaoying Shen
- Duke Human Vaccine Institute, Duke University Medical Center
- Robert Parks
- Duke Human Vaccine Institute, Duke University Medical Center
- Derrick Goodman
- Duke Human Vaccine Institute, Duke University Medical Center
- Amanda Eaton
- Duke Human Vaccine Institute, Duke University Medical Center
- Harikrishnan Balachandran
- Beth Israel Deaconess Medical Center, Harvard Medical School
- Linh V. Mach
- Beth Israel Deaconess Medical Center, Harvard Medical School
- Kevin O. Saunders
- Duke Human Vaccine Institute, Duke University Medical Center
- Joshua A. Weiner
- Dartmouth College
- Richard Scearce
- Duke Human Vaccine Institute, Duke University Medical Center
- Laura L. Sutherland
- Duke Human Vaccine Institute, Duke University Medical Center
- Sanjay Phogat
- Sanofi Pasteur
- Jim Tartaglia
- Sanofi Pasteur
- Steven G. Reed
- Infectious Disease Research Institute
- Shiu-Lok Hu
- Department of Pharmaceutics, University of Washington
- James F. Theis
- Public Health Research Institute, New Jersey Medical School, Rutgers University
- Abraham Pinter
- Public Health Research Institute, New Jersey Medical School, Rutgers University
- David C. Montefiori
- Duke Human Vaccine Institute, Duke University Medical Center
- Thomas B. Kepler
- Department of Microbiology, Boston University
- Kristina K. Peachman
- US Military HIV Research Program, Walter Reed Army Institute of Research
- Mangala Rao
- US Military HIV Research Program, Walter Reed Army Institute of Research
- Nelson L. Michael
- US Military HIV Research Program, Walter Reed Army Institute of Research
- Todd J. Suscovich
- Ragon Institute of MGH, MIT, and Harvard
- Galit Alter
- Ragon Institute of MGH, MIT, and Harvard
- Margaret E. Ackerman
- Dartmouth College
- M. Anthony Moody
- Duke Human Vaccine Institute, Duke University Medical Center
- Hua-Xin Liao
- Duke Human Vaccine Institute, Duke University Medical Center
- Georgia Tomaras
- Duke Human Vaccine Institute, Duke University Medical Center
- Guido Ferrari
- Duke Human Vaccine Institute, Duke University Medical Center
- Bette T. Korber
- Los Alamos National Laboratories
- Barton F. Haynes
- Duke Human Vaccine Institute, Duke University Medical Center
- DOI
- https://doi.org/10.1038/ncomms15711
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
A previous human HIV-1 vaccine clinical trial, boosting with HIV envelope protein from two strains, demonstrated moderate vaccine efficacy. Here, Bradleyet al. show that a pentavalent HIV envelope protein boost improves protection from viral challenge in non-human primates and they identify immune correlates of protection.
